New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2013
16:35 EDTSWIR, VMW, NTGR, VLO, EMC, KERX, PFE, HES, F, DHI, LLYOn The Fly: Closing Wrap
Stocks on Wall Street were mixed as the Dow closed only 200 or so points away from a high it has not reached since October 2007. A less-than-stellar consumer confidence reading for January stalled the advance early in the session, but the averages all rebounded and closed at or near their best levels of the day, though the Nasdaq was unable to hold in positive ground... ECONOMIC EVENTS: In the U.S., the November S&P/Case-Shiller 20-city Home-Prices Index was up a seasonally adjusted 0.6% from the prior month, versus expectations for a 0.7% increase. On a year-over-year basis, the 20-city index rose 5.5%, which was nearly in-line with consensus. The Consumer Confidence reading for January fell to 58.6, versus expectations for a smaller decline to 64.0... COMPANY NEWS: Ford (F) reported quarterly results that beat expectations on both the top and bottom lines. However, concerns over Europe, where the company said it expects to lose about $2B in 2013, sent shares down 64c, or 4.64%, to $13.14... Pharma giants Pfizer (PFE) and Eli Lilly (LLY) both reported earnings that beat consensus estimates before the market opened and both rallied. Dow-member Pfizer led that index with a 3.2%, or 86c, advance to $27.70, while Lilly gained $1.68, or 3.19%, to $54.32... MAJOR MOVERS: Higher for the second straight day were shares of Hess (HES), up $5.63, or 9.01%, to $68.11 after gaining over 6% yesterday, and Keryx Biopharmaceuticals (KERX), up $2.30, or 38.01%, to $8.36 today after rising over 76% yesterday. Also higher after earnings reports were DR Horton (DHI), which gained $2.51, or 11.78%, to $23.82, and Valero (VLO), which added $4.96, or 12.78%, to $43.77. Among the noteworthy losers was VMware (VMW), down $21.18, or 21.54%, to $77.14 after its guidance disappointed the Street and the stock was downgraded by numerous firms. EMC (EMC), which holds a majority ownership stake in VMware and also reported last night, also lost $1.02, or 4.05%, to $24.18. Also lower were shares of NetGear (NTGR), down $4.45, or 10.9%, to $36.38 after agreeing to acquire Sierra Wireless's (SWIR) AirCard business assets for $138M in cash. Sierra Wireless (SWIR) advanced $1.69, or 18.45%, to $10.85 after the news... INDICES: The Dow was up 72.49, or 0.52%, to 13,954.42; the Nasdaq was down 0.64, or 0.02%, to 3,153.66; and the S&P 500 was up 7.66, or 0.51%, to 1,507.84.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 >>
September 22, 2015
17:35 EDTPFEHillary Clinton vows to cap out-of-pocket drug costs at $250 per month
Presidential candidate Hillary Clinton said in a tweet that, "Under my plan, I'll cap out-of-pocket drug costs for families. You won't have to pay more than $250/month for covered medications." Reference Link
16:00 EDTFOptions Update; September 22, 2015
Subscribe for More Information
08:23 EDTPFEAnalysts say buy select biotech stocks ahead of Clinton drug plan
Ahead of Presidential candidate Hillary Clinton laying out her plan to tackle "price gouging" in the specialty drug market at an event in Iowa later today, analysts at research firms Jefferies and Piper Jaffray are recommending select biotech stocks that they view as buys amid the weakness in the space. DEBATE: Biotech stocks broadly declined yesterday, with the NASDAQ Biotechnology index (IBB) sliding roughly 4.4%, after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on a 62-year-old drug that fights complication of AIDS and cancer. Furor around the sudden price hike for Turing's Daraprim reignited a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. The news also follows Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Pfizer's (PFE) Hospira, in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. Presidential candidate Hillary Clinton sent the debate to center stage yesterday by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan today to tackle "price gouging" in the specialty drug market. Clinton's proposal, which she'll outline in a speech in Iowa later today, would force pharmaceutical companies to reinvest their profits into research, allow for more generic and imported drugs and allow Medicare to negotiate lower drug costs and cap out-of-pocket expenses, according to details of the plan shared with USA Today. Zeke Emanuel, chair of medical ethics and health policy at the University of Pennsylvania, appeared on Nightly Business Report to discuss the problem of high drug prices and his suggested solutions. During his interview, Emanuel contended that giving Medicare the ability to negotiate drug prices may drive up prices for everyone else. DEFENSES: The Jefferies Biotechnology research team, led by Brian Abrahams, Eun Yang and Biren Amin, say their Washington D.C. consultants indicate the recent political rhetoric around drug pricing is unlikely to result in any substantive future policy changes that would impact biotech sector fundamentals. As such, they recommend using yesterday's selloff to buy select companies including Celgene (CELG), BioMarin (BMRN) and Alkermes (ALKS). Pricing concerns are nothing new, and will likely continue to be a headwind for the sector, the analysts tell investors in a research note. Hillary Clinton's proposal to combat drug pricing is likely to include "some combination of old and tried policies that have been out there for a few years," they write. The analysts also like shares of AMAG Pharmaceuticals (AMAG), Alder Biopharmaceuticals (ALDR) and Cempra (CEMP). Meanwhile, Piper Jaffray analyst Edward Tenthoff recommends buying shares of Vertex Pharmaceuticals (VRTX) following yesterday's selloff. Tenthoff believes that drugs like Vertex's Orkambi will maintain premium pricing because of the disease modifying value to patients and payors. Orkambi is approved to treat cystic fibrosis in patients 12 years and older. The analyst reiterates an Overweight rating on Vertex with a $163 price target. DOWNGRADE: Brean Capital analyst Difei Yang downgraded Horizon Pharma (HZNP) to Hold saying "unsettling recent developments" make the stock's premium valuation no longer justified. The public discussion on high drug prices is a negative for the company while its attempt to acquire Depomed (DEPO) is unlikely to result in a completed deal, Yang tells investors in a research note. Further, Horizon's prescription trends are showing weakness, said Yang, who views the stock as more risky than in the past. PRICE ACTION: Horizon closed yesterday down $2.93, or 9.2%, at $28.99, while Vertex dropped $5.97, or 4.8%, to $118.19. A number of the biggest stocks in biotechnology were also weak yesterday, with Gilead sliding about 2.5%, Amgen (AMGN) dropping 2.3%, Celgene declining 2.8% and Biogen (BIIB) falling more than 5.5%.
08:08 EDTVMWVMware expands relationship with SAP
VMware (VMW) announced the expansion of its relationship with SAP (SAP). SAP and VMware plan to integrate the ACE approach to enable secure, instant deployment and login of SuccessFactors and Concur mobile applications on iOS and Android devices. The ACE community also announced today 21 new members, growing more than seven-fold since its inception in March 2015.
08:08 EDTVMWVMware extends Samsung partnership to include AirWatch
Subscribe for More Information
07:43 EDTLLY, PFEDrug stocks could be hurt by focus on pricing, says Oppenheimer
Subscribe for More Information
07:29 EDTEMCEMC coverage assumed with a Buy at Goldman
Target $30.
06:21 EDTEMCEMC coverage assumed with a Buy at Goldman
Subscribe for More Information
06:19 EDTPFE, LLYClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
16:53 EDTDHIOn The Fly: Top stock stories for Monday
Stocks on Wall Street began the session in positive territory and remained there for most of the morning. The Nasdaq was the first index to show signs of weakness after Hillary Clinton pledged to address the high cost of specialty drugs, sinking multiple biotech stocks. The averages later recovered from their afternoon lows, with both the Dow and S&P posting gains and the Nasdaq narrowly finishing in the green after Monday's drug pricing debate. ECONOMIC EVENTS: In the U.S., existing home sales fell 4.8% to a 5.31M rate in August, versus expectations for them to be down 1.6% to a rate of 5.5M. Over the weekend, three Federal Reserve officials, namely San Francisco Fed President John Williams, St. Louis Fed President James Bullard and Richmond Fed President Jeffrey Lacker, all argued that an interest-rate increase is still warranted this year. COMPANY NEWS: Biotech stocks declined after privately-held Turing Pharmaceuticals made headlines by enacting a 5,000% price increase on its treatment for toxoplasmosis, reigniting a debate around drug prices that previously embroiled costly Hepatitis C drugs including AbbVie's (ABBV) Viekira Pak and Gilead's (GILD) Sovaldi and Harvoni. Presidential candidate Hillary Clinton sent the debate to center stage by criticizing the "outrageous" prices of specialty drugs and promising to lay out a plan tomorrow to tackle "price gouging" in the specialty drug market. The NASDAQ Biotechnology index fell roughly 4.4% following the attention paid to Turing's drug and Clinton's response... Shares of Volkswagen (VLKAY) trading in New York dropped 17.1% to $30.10 after the EPA and California Air Resources Board detected manipulations that violate U.S. environmental standards while testing certain Volkswagen diesel cars. The EPA said Volkswagen may face civil penalties of $37,500 for each vehicle not in compliance with federal clean air rules, which could total as much as $18B, according to Reuters... Apple (AAPL), which has previously been reported to be working on an electric car via its "Project Titan," is speeding up those efforts and setting 2019 as a target to ship its first vehicle, according to The Wall Street Journal. Shares of Tesla Motors (TSLA) were volatile following the Journal's report, but closed the day up 1.37% at $264.20. MAJOR MOVERS: Among the notable gainers was Atmel (ATML), which surged 12.65%, to $8.19 after agreeing to be acquired by German chipmaker Dialog Semiconductor in a deal valued at roughly $4.6B. Also higher was Starwood Waypoint (SWAY), which gained $2.89, or 12.70%, to $25.64 after announcing a stock-for-stock merger agreement with Colony American Homes. Additionally, Pandora (P) rose 8.17% to $21.31 after receiving an interim opinion from the Register of Copyrights regarding the company's agreements with Merlin and Naxos. Among the noteworthy losers was GoPro (GPRO), which fell $2.88, or 8.19%, to $32.27 after Barron's contended that the company's stock could plunge another 30% to $25 as Apple, Sony (SNE), and others pressure the company's "one-hit wonder" products. Also lower was Mallinckrodt (MNK), which lost $8.23, or 10.02%, to $73.87 after ANI Pharma (ANIP) announced plans to acquire two new drug applications from Merck (MRK) that could compete with Acthar, Mallinckrodt's largest product. Separately, D.R. Horton (DHI) dipped 2.91% after the August U.S. existing home sales report showed a 4.8% drop for the month. Note also that Lennar (LEN) slipped 0.27% after its quarterly earnings report beat analyst estimates. INDEXES: The Dow rose 125.61, or 0.77%, to 16,510.19, the Nasdaq added 1.73, or 0.04%, to 4,828.96, and the S&P 500 gained 8.94, or 0.46%, to 1,966.97.
14:28 EDTLLY, PFETuring CEO says will not change Daraprim price despite criticism
Subscribe for More Information
11:24 EDTLLY, PFEHillary Clinton vows to take on 'outrageous' specialty drug pricing
Hillary Clinton, on the heels of a Wall Street Journal report detailing Turing Pharmaceuticals' price hike to $750 from $13.50 per pill of a drug called Daraprim which treats a life-threatening parasitic infection, vowed to lay out a plan tomorrow to take on what she calls "price gouging" of specialty drugs. The presidential nominee stated in a tweet, "Price gouging like this in the specialty drug market is outrageous. Tomorrow I'll lay out a plan to take it on." The iShares Nasdaq Biotechnology Index (IBB) moved lower following Clinton's tweet.
10:05 EDTSWIR, NTGRHigh option volume stocks
Subscribe for More Information
10:00 EDTDHIOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AB InBev (BUD) downgraded to Sector Perform from Outperform at RBC Capital... Aircastle (AYR) downgraded to Underperform from Buy at BofA/Merrill... Atmel (ATML) downgraded to Hold from Buy at Craig-Hallum... Boston Properties (BXP) downgraded to Neutral from Buy at Mizuho... Buenaventura (BVN) downgraded to Neutral from Outperform at Credit Suisse... CARBO Ceramics (CRR) downgraded to Underperform from Sector Perform at Iberia... Cameron (CAM) downgraded to Sector Perform from Outperform at Iberia... D.R. Horton (DHI) downgraded to Hold from Buy at Deutsche Bank... General Finance Corp (GFN) downgraded on pricing pressures at Oppenheimer... Greenbrier (GBX) downgraded to Market Perform from Outperform at Wells Fargo... HCP (HCP) downgraded to Sell from Neutral at Goldman... Helmerich & Payne (HP) downgraded to Sector Perform from Outperform at Iberia... ImmunoGen (IMGN) downgraded to Underweight on IMGN 853 risk at Morgan Stanley... Janus Capital (JNS) downgraded to Underweight from Equal Weight at Morgan Stanley... Key Energy (KEG) downgraded to Sector Perform from Outperform at Iberia... Melco Crown (MPEL) downgraded to Underperform from Neutral at Macquarie... Olympic Steel (ZEUS) downgraded to Sector Weight from Overweight at KeyBanc... Potash (POT) downgraded to Underperform from Neutral at Macquarie... Precision Castparts (PCP) downgraded following acquisition at RBC Capital... Rocky Brands (RCKY) downgraded to Neutral from Buy at B. Riley... Sirona Dental (SIRO) downgraded to Equal Weight from Overweight at Stephens... Tribune Publishing (TPUB) downgraded to Underperform from Neutral at Macquarie... Trinity Industries (TRN) downgraded on lower growth outlook at Wells Fargo... Waddell & Reed (WDR) downgraded to Underweight from Equal Weight at Morgan Stanley... WisdomTree (WETF) downgraded to Equal Weight from Overweight at Morgan Stanley... ZS Pharma (ZSPH) downgraded to Equal Weight on valuation at Morgan Stanley.
09:06 EDTKERXKeryx management to meet with JPMorgan
Meeting to be held in the Mid-Atlantic area on September 24 hosted by JPMorgan.
08:36 EDTLLYBofa/Merrill pharmaceuticals analysts hold analyst/industry conference call
Analysts, along with diabetes experts Drs. Richard Pratley and Jochen Seufert, discuss the recent EMPA-REG OUTCOME data presented at the recently held European Association for Study of Diabetes (EASD) Annual Meeting including Eli Lilly's SGLT2 inhibitor, Jardiance (empagliflozin), on an Analyst/Industry conference call to be held on September 21 at 10 am.
08:03 EDTPFEPfizer says two Phase 3 tofacitinib 10mg trials met primary endpoints
Subscribe for More Information
07:21 EDTDHID.R. Horton downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
07:18 EDTDHITaylor Morrison upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Nishu Sood upgraded Taylor Morrison (MTHC) to Buy saying the company's value is not being recognized given its small market capitalization and acquisitions. Taylor's expected two-year book value accretion of 23% is also above the group average of 21%, Sood tells investors. He keeps a $26 price target for shares. The analyst coupled the upgrade with a downgrade of D.R. Horton (DHI) to Hold.
06:07 EDTLLYEli Lilly price target raised to $90 from $83 at JPMorgan
Subscribe for More Information
1 | 2 | 3 | 4 | 5 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use